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Smary This analysis was conducted to evaluate the independent relationship between survival and
response to chemotherapy in advanced colorectal cancer. In order to correct for the guarantee time effect,
patients dying before the response evaluation were excKlded from the analyses. A previously ans ted
prognostic model containing 11 variables was apple to 324 patints. When the response categories were
analysed together with the prognostic variabes, it was found that a response was associated with a definite
survival advantage (P<O.OO1), whereas the influence of all the other variables decr The corrected
survival advantage (relative progreive disa) was 11 months after a complete response, 6 months after a
partial response and 4 months after stable diseas. The survival advantage was of a similar matnitude when
the analyses were repeated in an independent population comprising 198 patients in whom the prognostic
model was extended to include also a set of laboratory values The results show that a response to
chemotherapy is associated with a longer survival also after correction for the guarantee time effect and the
distribution of prognostic variables.
5-Fluorouracil as a single drug was for many decades the
standard treatment in advanced colorectal cancer, but re-
sponse figures seldomly exceeded 20% and there is no evi-
dence that this treatment prolonged survival (Moertel, 1975).
More recently, several trials have investigated the effects of
biochemical modulation of 5-FU, particularly with metho-
trexate or leucovorin (K6hne-W6mpner et al., 1992). The
response rates were generally higher in the combination arms
compared with 5-FU alone, and a survival prolongation was
also seen in a few of the individual trials. A survival advant-
age of about 5 months was observed in patients receiving
immediate combination chemotherapy as compared with
those receiving delayed (Nordic Gastrointestinal Tumor
Adjuvant Therapy Group, 1992) or no treatment (Scheith-
auer et al., 1993). These results suggest that combination
chemotherapy based on biochemical modulation of 5-FU can
prolong survival.
It is generally believed that a beneficial effect of
chemotherapy is obtained in patients in whom an objective
response is recorded. However, several questions can be
asked about the intrinsic value of a response. A recent meta-
analysis was not able to verify that patients treated with
5-FU and leucovorin experienced a longer survival than
those who received 5-FU alone despite higher response rates
in the former group (Advanced Colorectal Cancer Meta-
analysis Project 1992). A small but definite survival prolonga-
tion did, however, accompany improved response rates in
patients receiving 5-FU and methotrexate in a subsequent
meta-analysis (Advanced Colorectal Cancer Meta-analysis
Project 1994). Another unresolved matter concerning the true
value of a response is whether responses mainly occur in
patients with a favourable prognosis, which would explain
why responders invariably have a longer survival than non-
responders (Lavin et al., 1980). An additional bias that may
contribute to the longer survival seen among responders is
the guarantee time effect, i.e. that responders are guaranteed
a survival as long as the time to the response evahuation
(Anderson et al., 1983). Correction for the guarantee time
effect and differently distributed prognostic variabks would
thus clarify the role of a response as both a clinical and
scientific variable.
The present study was conducted to estimate the survival
gain in the currently used response categories after adjust-
ment for the guarantee time effect and different distributions
of prognostic signs. The analyses were first performed on one
group of patients and subsequently repeated in an indepen-
dent group in order to test the validity of the results.
Material and
Patients included in four chemotherapy trials were studied
(Gimeius et al., 1986; Nordic Gastrointestinal Tumor
Adjuvant Therapy Group, 1989, 1992, 1993). The following
inclusion criteria were applied in all trials: metastatic or
locally recurrent/inextirpable colorectal cancer, age 75 or
younger, Karnofsky performance status 50 or higher, serum
creatinine <125mmoll-1, serum bilirubin <40mmoll-1
and no signs of pleural effusion or ascites. Inclusion criteria
differed in two respects between the trials: patients previously
treated with chemotherapy were eligible only in the phase II
trial (Glimelius et al., 1986) and patients with non-
measurable disease only in one of the phase HI trials (Nordic
Gastrointtinal Tumor Adjuvant Therapy Group, 1992).
The following requirements had to be met for inclusion in
the present study: no previous chemotherapy, at least one
course of chemotherapy ad and measurable
diseas. The first population comprised 324 patients treated
with either 5-FU alone or sequential methotrexate/5-FU/
leucovorin (MFL), and the second population 198 patients
treated with MFL or sequential 5-FU and leucovorin (ELv)
(Table I). We have earlier described prognostic factors in
these populations (Graf et al., 1991, 1994). Survival time was
measured from on-protocol time to death from any cause. At
the time ofanalysis, 22 patients were alive in the first popula-
tion (median follow-up 18 months, range 10-72) and 15 in
the second population (median follow-up 19 months, range
13-31).
The evaluation of objective responses followed the UICC
recommendations (Hayward & Rubens, 1977). Briefly, in
order to qualify as a complete response (CR) all known
tumour must have disappeared. A partial response (PR) was
present when the sum of all measurable lsions had decreased
by at least 50%. It was not necessary that all individual
lesions had reressed, but no tumour was allowed to increase
by more than 25% and no new growths should be observed.
Stable disease (SD) was defined as between a 50% decrease
and 25% increase. In all other instanes progressive disase
(PD) was registerd. In case of multiple lesions, e.g. in the
liver, measurements were made of the three largest ones. A
CR, a PR and SD had to be present at two consecutive
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Table I Characteristics of clinical trials in the present study
Trial
1 2 3 4
Population 1 1 1 2
Reference Glimelius (1986) NGTATG (1989) NGTATG (1992) NGTATG (1993)
Time penrod 1982-84 1985-87 1985-90 1988-90
Measurable diseases 48 233 43 198
Survival >4 monthse 41 161 40 154
Type of trial Phase II Phase III Phase III Phase III
Institution Single Multicentre Multicentre Multicentre
Randomisation - MFL vs 5-FU MFL vs 0 MFL vs FLv
Treatment'
MFL 48 113 43 98
5-FU - 120 - -
FLv - 100
'Number of patients. MFL, sequential methotrexate/5-FU/leucovorin; FLv, sequential
5-FU leucovorin; NGTATG, Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
evaluations (Miller et al., 1981). The first evaluation was
made after 2 months and subsequent evaluations every
second month, i.e. all patients assigned a response or SD
were guaranteed a survival of 4 months.
Statistical methods
Except for the first life table in the two populations, all
calculations were based on individuals alive after 4 months,
which means that the 'landmark method' was used to remove
the bias caused by the 'guarantee time' effect (Anderson et
al., 1983). The initial analyses involved the first population.
Survival curves were constructed with the actuarial method
and differences assessed with the log-rank test. The distribu-
tion of patients characteristics by response was evaluated
with chi-square or t-tests, as appropriate. Patients with a
response or SD were considerd together in these analyses.
The response categories were then tested together with 11
other variables in a Cox (1972) proportional hazards model
for influence on survival. The variables in this model were
capable of prediction of prognosis in a previous study (Graf
et al., 1991). The results are presented as relative hazards
(RH) and 95% confidence limits within parentheses (PD =
reference). The use of the multivariate methods can be
viewed as a generalisation of the landmarkl method adjusting
the estimates for differently distributed prognostic factors.
Models in which the hazards were allowed to change over
time were also employed. Estimates of survival times con-
nected with each response category were obtained from a
model based on the extended generalised gamma distribution
(Lawless, 1982).
All analyses were then repeated in the second population
to determine if the results could be reproduced in an
independent group. In this model, a group of laboratory
values were also included, giving a total of 17 variables. This
set of variables could also define subsets of individuals ac-
cording to prognosis (Graf et al., 1994). A detailed descrip-
tion of the statistical methods is given in an appendix.
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Figwe 2 Probability of survival in patients in the first popula-
tion alive after 4 months (n = 242) according to response (CR,
PR, SD and PD).
Results
First population
Twelve patients had a CR, 40 a PR, 113 SD and 159 PD.
Median survival after CR was 21 months, after PR 15
months, after SD 12 months and after PD 4 months [log-
rank X2 (3) = 166, P<0.001, Figure 1J. After exclusion of 82
patients who survived less than 4 months, median survival
time for the PD group increased to 7 months, which was still
clearly inferior to the other categories (log-rank xJ (3) = 64,
P<0.001, Figure 2]. With a few exceptions, patient charac-
teristics did not differ much between the PD group and those
with a response or SD (Table II).
In a Cox multivariate model, the response categories CR,
PR and SD (PD = reference category) were the most impor-
tant variables (P<O.0001). In addition, the haemoglobin
(B-Hb) level at trial entry (P = 0.001) and disease-free inter-
val (P = 0.006) contained prognostic information (Table III).
The results of multivariate models in which the hazards were
allowed to change over time showed that the effect of the
response categories decreased after the landmark time point
(data not shown). The following median survival times in
months (after 4 months) were computed for individuals with
all other explanatory variables set at their means (standard
errors in parentheses): CR 14.8 (4.4), PR 10.1 (1.5), SD 7.8
(0.7) and PD 3.5 (0.5).RESPONSE AND SURVIVAL IN ADVANCED COLORECTAL CANCER 561
Table H Characteristics of patients surviving more than 4 months according to whether a response or
progressive disease was recorded
First population Second population
CR + PR + SD PD CR + PR + SD PD
(n = 165) (n = 77) (n =85) (n =69)
Age 62 (34-75) 61 (33-74) 62 (37-75) 62 (23-75)
Men-women 98:67 (59:41) 39:38 (51:49) 50:35 (59:41) 39:30 (57:43)
Colon-rectum 91:74 (55:45) 45:32 (58:42) 55:30 (65:35) 46:23 (67:33)
Primary tumour 146:19 (89:11) 71:6 (92:8) 70:15 (82:18) 59:10 (86:14)
resected, yes/no
KPS 85 (60-100) 80 (50-100)* 79 (60-90) 75 (60-90)*
No. of symptoms 1.3 (0-4) 1.7 (0-4)** 1.8 (1-4) 2.0 (1-4)
Disease-free interval (days) 457 (0-4414) 329 (0-3437) 575 (0-3287) 620 (0-9999)
B-Hb (g l-') 127 (84-165) 125 (89-174) 125 (80-165) 125 (93-158)
Metastatic site, yes/no
Liver 92:73 (56:44) 54:23 (70:30)* 60:25 (71:29) 46:23 (67:33)
Lung 60:105 (36:64) 25:52 (32:68) 26:59 (31:69) 21:48 (30:70)
Lymph nodes 35:130 (21:79) 15:62 (19:81) 22:63 (26:74) 16:53 (23:77)
Peritoneal 17:148 (10:90) 6:71 (8:92) 6:79 (7:93) 9:60 (13:87)
Local 53:112 (32:68) 30:47 (39:61) 25:60 (29:71) 27:42 (39:61)
Other 23:142 (14:86) 11:66 (14:86) 10:75 (12:88) 9:60 (13:87)
No. of sites 1.7 (1-4) 1.8 (1-4) 1.8 (1-4) 1.9 (1-3)
Figures are numbers and (percentages) or means and (range). *P <0.05, **P <0.01. KPS, Karnofsky
performance status; CR, complete response; PR, partial response; SD, stable diseas; PD, progressive disease.
B-Hb, haemoglobin level.
Table m The influence of response and other characteristics on
survival in a Cox multivariate analys assuming proportional
hazards. The calulation is based on the first population comprsing
242 patients alive after 4 months
Characteristic RH (95% CL) P-vahle
Complete response 0.17 (0.08-0.37) <0.0001
Partial response 0.29 (0.18-0.45) <0.0001
Stable disease 0.40 (0.29-0.56) <0.0001
Progressive disease Reference
B-Hb 0.98 (0.97-0.99) <0.001
Disease-free interval (days
365 0.64 (0.47-0.88) <0.01
<365 Reference
Included but insignificant variables (P>0.10): age, sex, location
of primary (colon vs rectum), primary resected or not, Karnofsky
performance status, number of metastatic sites, number of
symptoms, trial, treatment (MFL vs 5-FU). RH, relative hazards;
CL, confidence limits. B-Hb, haemoglobin leel.
Secondpopulation
A CR was observed in four patients with a median survival
of more than 31 months, a PR in 34 patients who experi-
enced a median survival of 13 months, SD in 47 individuals
with a median survival of 12 months and finally PD in the
remaining 113 patients who had a median survival of 5
months [X (3) = 113, P<0.001, Figure 3]. After exclusion of
44 patients with PD and survival less than 4 months, median
survival for the PD group rose to 7 months, which was still
clearly shorter than the other groups [Xy (3) = 73, P<0.001,
Figure 4]. Except for a slightly higher Karnofsky perform-
ance status, the characteristics of the patients did not differ
appreciably between the response plus SD group versus the
PD group (Table II).
In a full multivariate analysis with 17 variables, the re-
sponse categories had again the strongest relationship to
survival (Table MV). Median survival estimates (after 4
months) with all other variables set at their means were 36.2
months (26.6) for CR, 9.8 months (1.4) for PR, 7.8 months
(0.9) for SD and 2.8 months (0.3) for PD.
Disussion
This study showed that although the guarantee time accounts
for some of the survival advantage connected with a re-
sponse, responders also lived much longer than non-re-
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Fugwe 4 Probability of survival in patients in the second
population alive after 4 months (n = 154) according to response
(CR, PR, SD and PD).
sponders when the analyses were restricted to patients alive
after 4 months, i.e. the minimum survival time to qualify as a
responder. Furthermore, adjustment of the differences in
patient composition between the responders and non-respon-
ders did not result in any major decrease in the importance
of a response. Patients with a response were thus not a
preselected group, at least not based on the variables
included in our models. This finding has clinical implications562 W. GRAF et al.
Table IV The influence of response on survival adjusted for the
effects of 16 other variables. The calculation is based on the second
population comprising 154 patients alive after 4 months
Response category RH (95% CL) P-value
Complete response 0.03 (0.004-0.24) <0.0001
Partial response 0.19 (0.12-0.31) <0.0001
Stable disease 0.27 (0.17-0.41) <0.0001
Progressive disease Reference
Age 1.04 (1.02-1.07) <0.001
B-Hb 0.98 (0.97-0.99) <0.01
S-ALAT 1.80 (1.00-3.24) <0.05
Included but insignificant variables (P >0.10): sex, primary colon
or rectum, KPS, treatment of the primary tumour, no. of tumour
sites, no. of symptoms, disease-free interval, white blood cell count,
B-thrombocytes, serum creatinine, serum biLirubin, serum alkaline
phosphatase. serum aspartate aminotransferase.
in the sense that responses are not restricted to 'good-
prognosis' patients. and therapy may be indicated also in the
presence of adverse prognostic signs.
A previous analysis of the first population revealed that
MFL treatment, B-Hb. disease-free interval, number of
symptoms, Karnofsky performance status and resection of
the primary tumour were important predictors of survival
(Graf et al., 1991). When response category was included in
the analysis, only B-Hb and disease-free interval retained
significant prognostic information, whereas MFL lost all prog-
nostic value. This result suggests that the beneficial effect of
therapy is expressed in the response or stabilisation effect or,
in other words, the type of chemotherapy regimen did not
matter for those with progressive disease. Response is thus
not just another independent predictor of survival but, at
least in this study, the main explanatory variable supporting
its use as an end point in clinical trials. An opposite con-
clusion was reached in the meta-analysis of 5-FU and leuco-
vorin vs 5-FU alone, in which no survival advantage was
detected in spite of higher response rates in the former group
(Advanced Colorectal Cancer Meta-analysis Project 1992). In
addition to the possible explanations for this result proposed
by the authors, an alternative explanation might be con-
sidered in light of the present findings. In most studies,
including the present ones, internationally accepted response
criteria have been followed (Miller et al., 1981). The criteria
may, however, be more or less strictly applied.
The above-mentioned meta-analysis included studies using
minimum response durations of 4 or 8 weeks. This means
that in some studies two response evaluations at least 4
weeks apart were not possible. This short interval may act to
weaken an association between response and survival. In
contrast, the interval between the response evaluations was
always 8 weeks in the present study, and the first was not
until after 8 weeks. Furthermore, all responses were inde-
pendently reviewed. It is possible that these strict criteria
increased the likelihood of detecting an association between a
response and a prolonged survival.
There are two possible explanations for the strong associa-
tion between a response and survival: the response may cause
the survival prolongation or it may just be a marker for one
or several factors that were not included in the analysis. This
issue is impossible to settle since one cannot account for all
possible prognostic markers. However, in an attempt to
challenge our results in the first population, we repeated the
analyses in an independent group including also a group of
laboratory values in the model. The relationship between
response and survival was of a similar magnitude in this
second analysis, thus favouring a casual relationship rather
than an association.
Our results are in agreement with those of A'Hern et al.
(1988) in advanced breast cancer, who found that survival
was longer in trial arms with higher response rates. The
survival prospects improved evenly for each response cate-
gory. indicating an inverse relationship between changes in
size of the target lesions and survival. It is noteworthy that
disease stabilisation implied a survival advantage compared
with PD of the same magnitude as that between SD and PR.
A similar observation was made by Paterson et al. (1985) in
patients with metastatic breast cancer. We have previously
noted a strong correlation between an objective and a subjec-
tive response. when patients with a response or SD were
subjectively improved almost to the same extent (Glimelius et
al., 1989, 1994; Carlsson et al., 1990). In light of these
findings, it seems reasonable to include patients with SD in
some form of 'desirable' response category, provided the
stabilisation lasts for a minimum of 4 months.
In conclusion, a response to chemotherapy of 4 months'
duration in advanced colorectal cancer is associated with a
survival advantage also after correction for the guarantee
time effect and the distribution of prognostic variables
between the response and non-response groups.
Statstical appendx
In order to study the effect on survival of different ex-
planatory variables, the Cox (1972) proportional hazards
model was used. In this model, it is assumed that the hazard
('the instantaneous death rate') h(t,x) can be written:
h(t x) = ho(t) exp(flxl +... + PkXk)
where ho(t) is a baseline hazard function for individuals with
all explanatory variables x1,...,xk equal to 0. The parameter Pi
represents the change in the logarithm of the hazard function
as the variable xi increases by one unit, given that the other
variables are unchanged. A positive value of Pi implies an
increase in the hazard function, i.e. poorer survival prospects.
The effect on the hazard associated with the variable xi is
exp(ii), which we denote the relative hazard (RH). For a
categorical variable (e.g. response), the RH shows the hazard
for an individual in a certain category such as SD compared
with an individual in the reference category, in this case PD.
For a variable in continuous form (e.g. B-Hb) the RH shows
the effect on the hazrd associated with increasing the
variable by one unit.
The Cox proportional hazards model is the most com-
monly used method of analysing the effect of different
variables on survival. The key assumption underlying this
model is that of proportional hazards. One definite advant-
age of the Cox model is that the baseline hazard function
need not be specified, which means that the model is more
general than models based on specific distributions in the
proportional hazards class. One disadvantage of the Cox
model is that the proportional hazards assumption need not
be true. In order to avoid the proportionality assumption,
which is not fulfilled in the present study, we have general-
ised the basic proportional hazards model in two ways. One
is by the use of time-dependent covariates which allow the
relative hazards to change over time according to the follow-
ing expression for each explanatory variable:
h(t) =ho(t)exp(pxi + lxiflog (time)-log 120])
The parameter Po shows the effect of the variable xi at the
reference time point (in this case 120 days), while PI shows
how the effect changes over time. Other relationships have
also been tried and produce qualitatively similar results. As a
second approach, the relative hazard was assumed to be
constant within certain time intervals but allowed to change
between intervals. The result of this approach was similar to
those reported.
A property of the Cox model is that it is formulated in
terms of hazards and not in the often more easily understood
survival time. Although it is possible to obtain estimates of
survival time from a Cox model, this cannot be accomplished
in a simple way. In view of this and the doubt concerning the
proportional hazards assumption it was preferable to
estimate median survival times from a model that does not
imply a proportionality assumption. To accomplish this, a
regression-type model, which relates survival time (or a func-
tion of survival time) to the explanatory variables, was used.RESPONSE AND SURVIVAL IN ADVANCED COLORECTAL CANCER 563
One such model with great generality is based on the ex-
tended generalised gamma (EGG) distribution (Lawless,
1982). If survival time T is assumed to follow such a distribu-
tion, log survival time can be written as:
log T=Po+Blxl + ... +Pkxk+ z
where a is a scale parameter and z follows a complicated
distribution characterised by a shape parameter gamma. One
extremely important feature of this model is that it includes
several well-known models as special cases and can be used
to distinguish between these models. In the special case y =0,
survival time follows a log-normal distribution, while for
=1 survival time is Weibull distributed.
Compared with the Cox model, the model based on the
EGG distribution is more general in the sense that it allows
non-proportional hazards. It is less general as restrictions on
the baseline hazards are imposed. The EGG model and some
of its important special cases were estimated by the maxi-
mum likelihood method. The exact choice of distribution did
not greatly change the conclusions regarding the median
survival time in the response categories, nor was the impor-
tance of the explanatory variables sensitive to the choice of
survival distributions. In addition to members of the ex-
tended generalised gamma family, the log-logistic distribution
was employed.
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